COVID-19;アビガンを開発した白木公康先生の総説を読んで下さい。

中年以降の患者は早めにアビガンを飲んでもらうべきと思います。

アビガンが開発した白木公康先生の総説を読んで下さい。

緊急寄稿（1）新型コロナウイルス感染症（COVID-19）のウイルス学的特徴と感染様式の考察（白木公康）

https://www.jmedj.co.jp/journal/paper/deail.php?id=14278

緊急寄稿（2）新型コロナウイルス感染症（COVID-19）治療候補薬アビガンの特徴（白木公康）

https://www.jmedj.co.jp/journal/paper/detail.php?id=14305

緊急寄稿（3）新型コロナウイルス感染症（COVID-19）を含むウイルス感染症と抗ウイルス薬の作用の特徴（白木公康）

https://www.jmedj.co.jp/journal/paper/detail.php?id=14354

April 13, 2020

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)A Review

https://jamanetwork.com/journals/jama/fullarticle/2764727?guestAccessKey=72e8a5f3-3754-4bf8-bb17-8c2f1cf358b0&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=041320

Favipiravir

Favipiravir, previously known as T-705, is a prodrug of a purine nucleotide, favipiravir ribofuranosyl-5′-triphosphate. The active agent inhibits the RNA polymerase, halting viral replication. Most of favipiravir’s preclinical data are derived from its influenza and Ebola activity; however, the agent also demonstrated broad activity against other RNA viruses.⁶⁷ In vitro, the EC₅₀ of favipiravir against SARS-CoV-2 was 61.88 μM/L in Vero E6 cells.⁵⁸

Various dosing regimens have been proposed based on the type of infectious indication. Dosing variations are likely due to the lower favipiravir EC₅₀ values described against influenza compared with Ebola and SARS-CoV-2.^68,69 Doses at the higher end of the dosing range should be considered for the treatment of COVID-19.⁶⁹A loading dose is recommended (2400 mg to 3000 mg every 12 hours × 2 doses) followed by a maintenance dose (1200 mg to 1800 mg every 12 hours). The half-life is approximately 5 hours.⁷⁰ The agent has a mild adverse effect profile and is overall well-tolerated, although the adverse event profile for higher-dose regimens is limited.^44,69,71,72 Favipiravir is currently available in Japan for the treatment of influenza, but not available in the United States for clinical use.

Limited clinical experience has been reported supporting the use of favipiravir for COVID-19. In a prospective, randomized, multicenter study, favipiravir (n = 120) was compared with Arbidol (n = 120) for the treatment of moderate and severe COVID-19 infections. Differences in clinical recovery at day 7 were observed in patients with moderate infections (71.4% favipiravir and 55.9% Arbidol, P = .019). No significant differences were observed in the severe or severe and moderate (combined)

arms.⁷³ These data support further investigation with RCTs of the efficacy of favipiravir for the treatment of COVID-19.

Pharmacology & Therapeutics

Volume 209, May 2020, 107512

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

https://www.sciencedirect.com/science/article/pii/S0163725820300401

エボラウイルスに対するアビガンのin vitroでの有効性
μg/mLでの記載もあり。
以前に紹介した論文で示されたように、SARS-CoV2に対するアビガンは常用量で少なくともin vitroでは有効。
https://t.co/e6Qj2uLmPv

— ニューロドクター乱夢 (@hichachu) April 30, 2020

図1
細胞培養におけるEBOVに対するT-705の抗ウイルス活性。（A）Vero E6細胞にEBOVを感染させ、T-705を piで1 時間追加した、5 日後、細胞培養上清中の感染性ウイルス粒子の濃度をイムノフォーカスアッセイで測定した。https://t.co/n75CgeL2Di

— ニューロドクター乱夢 (@hichachu) April 30, 2020

 

クリックして2020.03.17.20037432v1.full.pdfにアクセス

http://blog.with2.net/link.php/36571（ブログランキングに登録しています）